Innovent Biologics' Efdamrofusp Alfa Marks a Milestone for nAMD Treatment in China Innovent Biologics' recent study shows Efdamrofusp Alfa is the first self-developed medication achieving extended treatment intervals for nAMD in China.

Innovent Biologics' Efdamrofusp Alfa Marks a Milestone for nAMD Treatment in China #China #Suzhou #Innovent_Biologics #Efdamrofusp_Alfa #nAMD

Rapid fluid resolution may signal reduced faricimab injection frequency in nAMD Early retinal drying in people with neovascular age-related macular degeneration receiving faricimab treatment may signal improved disease control that allows subsequent injection intervals to be…

#MedNews - Early retinal drying in people with neovascular age-related macular degeneration receiving #faricimab treatment may signal improved disease control that allows subsequent injection intervals to be extended.

Full story 👉 buff.ly/dJtmk3A

#EyeSky #nAMD

TALON phase IIIb study: 64 week results of brolucizumab versus aflibercept using treat-and-extend for neovascular age-related macular degeneration - PubMed The Week 64 results in TALON reaffirmed those reported at Week 32, demonstrating extended treatment intervals and an overall favourable benefit/risk profile for brolucizumab in patients with nAMD.

New TALON Phase IIIb results: brolucizumab enables more nAMD patients to reach 16-week treat-and-extend dosing vs aflibercept, with comparable vision gains—less treatment burden.
#nAMD #Retina #Ophthalmology #ClinicalTrials #MedTwitter #VisionResearch buff.ly/OI1TPGZ

Glucagon-Like Peptide-1 Receptor Agonists and Risk of Neovascular Age-Related Macular Degeneration This cohort study conducted in Ontario, Canada, evaluates the risk of developing neovascular age-related macular degeneration associated with the use of glucagon-like peptide-1 receptor agonists in pa...

Uso de GLP1RA en pacientes con diabetes se asocia con un riesgo 2 veces mayor de desarrollar degeneración macular neovascular asociada con la edad #glp1ras #nAMD #diabetes jamanetwork.com/journals/jam...

Management of fibrosis in neovascular age-related macular degeneration Subretinal fibrosis is a common end-stage sequela of neovascular age-related macular degeneration (nAMD), and it is associated with poor long-term visual outcomes. The pathogenesis of subretinal…

What are the mechanisms and risk factors for fibrosis in #nAMD?

Understand what is driving this common end-stage phenomenon, and the limitations of current detection methods.

👉 buff.ly/B3OtyXB

#EyeSky

Aflibercept offers sustained nAMD control at extended dosing intervals Aflibercept provides sustained visual acuity for up to 2 years in patients with neovascular age-related macular degeneration when given at a dose of 8 mg every 12 or 16 weeks.

#MedNews - #Aflibercept provides sustained visual acuity for up to 2 years in patients with #nAMD when given at a dose of 8 mg every 12 or 16 weeks.

Full story 👉https://buff.ly/o2TNBm9

#EyeSky

Faricimab and aflibercept offer optimal balance in nAMD treatment Faricimab 6 mg and aflibercept 8 mg may offer the best balance between visual and anatomical outcomes and treatment burden in neovascular age-related macular degeneration.

From #EURETINA25 - Faricimab 6 mg and aflibercept 8 mg may offer the best balance between visual and anatomical outcomes and treatment burden in neovascular age-related macular degeneration.

👉https://buff.ly/tEriVcQ

#EyeMed #MedNews #nAMD

❗ LAST CHANCE TO REGISTER ❗

Join our experts to explore the groundbreaking advances in retinal imaging and gene therapy, before taking a deep dive into emerging treatments for #nAMD.

Register now 👉 buff.ly/BSZphUA

#EyeSky #EyeMed #MedEd

GLP-1 receptor agonist use linked to neovascular age-related macular degeneration risk Risk of new-onset neovascular age-related macular degeneration in patients with diabetes more than doubles with use of glucagon-like peptide-1 receptor agonists for 6 months.

#MedNews - Risk of new-onset neovascular age-related macular degeneration in patients with #diabetes more than doubles with use of #GLP1 receptor agonists for 6 months.

Full story 👉 buff.ly/UqdYPAB

#EyeMed #nAMD

#NeovascularAgerelatedMacularDegeneration #nAMD

APEX1 redox-specific inhibitor APX2009 (intravitreal) ⏬🐭👁️pathological #Angiogenesis

Laser-induced #ChoroidNeoVascularization
Vldlr-/- mouse subretinal neovascularization

Timothy Corson lab #Angiogenesis 2025
link.springer.com/article/10.1...

🚨 Applications are open for the 63rd Hands-on Workshop on Computational Biophysics at Auburn University!

📍 Auburn University | 📅 Aug 4–8, 2025
🔬 Learn #NAMD, #VMD from experts in #moleculardynamics
👩‍💻 In-person | Free to apply | 35 spots only
⏳ Deadline: June 20
🔗 aub.ie/Workshop2025

Are you using nonadiabatic dynamics for complex systems? Join us in sunny Spain for the "Future Directions in Non-Adiabatic Dynamics" workshop (Sept 2-5, 2025) at CECAM-Zaragoza! Register by June 3. Check out the event page: tinyurl.com/2nvnanf2

#NAMD #NonAdiabaticDynamics #CECAM

💻 Call for the Nonadiabatic Molecular Dynamics community!

We're working toward molecular benchmarks to navigate method selection. Our Roadmap is now on ArXiv, and we welcome your feedback!

📄 Read: arxiv.org/abs/2502.14569
📩 Send comments by 16/03

#NAMD #ComputationalChemistry #MolecularDynamics

Faricimab versus the standard of care for neovascular age-related macular degeneration in Italy: an indirect treatment comparison <div xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="section"> <a class="named-anchor" id="st1"> <!-- named anchor --> </a> <h5 c...

👁️ Faricimab vs. anti-VEGF treatments for nAMD: Could it improve outcomes in Italy? @aboutscience.bsky.social

🔗 www.scienceopen.com/document?vid...

#nAMD #ClinicalResearch

Starting now the 62nd Hands-on workshop on computational Biophysics ! Excited to share about intro and new updates on #namd and #VMD!

Today’s #JournalClub by Alessandro discusses ways to facilitate nonadiabatic dynamics #NAMD with #MachineLearning #DeelLearning, developed by Westermayr, Gonzalez, Dral, Cui, et al. #compchem www.h-its.org/research/ccc...